证券代码：301122 证券简称：采纳股份 公告编号：2023-072 采纳科技股份有限公司 关于向金融机构申请综合授信额度的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 采纳科技股份有限公司（以下简称"公司"）第三届董事会第二次会议审议 通过了《关于公司向金融机构申请综合授信额度的议案》，现将相关情况公告如 下： 为满足公司及其下属全资子公司的生产经营的需求，并考虑到资金的合理配 置和利用，公司拟向金融机构申请授信额度不超过 15,000 万元的综合授信。 综合授信内容包括但不限于流动资金贷款、各类商业票据开立及贴现、项目 贷款、银行保函、保理、银行承兑汇票、开立信用证等综合授信业务（具体业务 品种以相关金融机构审批为准）。各金融机构具体授信额度、贷款利率、费用标 准、授信期限等以公司与金融机构最终协商签订的授信申请协议为准。上述综合 授信额度的申请期限为董事会审议通过之日起 12 个月止，该授信额度可用于公 司及其下属全资子公司，在申请期限内可循环使用。 公司拟授权董事长办理授信及提供质押增信措施等所有授信事宜，包括但不 限于与授信、借款、抵押、担 ...

海通证券股份有限公司关于采纳科技股份有限公司 2023 年半年度跟踪报告 | 保荐机构名称：海通证券股份有限公司 | 被保荐公司简称：采纳科技股份有限公司 | | --- | --- | | 保荐代表人姓名：钟祝可 | 联系电话：021-23185939 | | 保荐代表人姓名：张刚 | 联系电话：021-23187055 | 一、保荐工作概述 | 项 目 | 工作内容 | | --- | --- | | 1、公司信息披露审阅情况 | | | （1）是否及时审阅公司信息披露文件 | 是 | | （2）未及时审阅公司信息披露文件的次数 | 不适用 | | 2、督导公司建立健全并有效执行规章制度的情况 | | | （1）是否督导公司建立健全规章制度（包括但不限于 防止关联方占用公司资源的制度、募集资金管理制度、 内控制度、内部审计制度、关联交易制度） | 是 | | （2）公司是否有效执行相关规章制度 | 是 | | 3、募集资金监督情况 | | | （1）查询公司募集资金专户次数 | 6 | | （2）公司募集资金项目进展是否与信息披露文件一致 | 是 | | 4、公司治理督导情况 | | | （1）列席公司股 ...

证券代码：301122 证券简称：采纳股份 公告编号：2023-073 采纳科技股份有限公司 第三届董事会第二次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 2、审议通过了《关于 2023 年半年度募集资金存放与实际使用情况的专项报 告》 经审议，该专项报告主要从募集资金的存放和实际使用情况等方面反应了 2023 年上半年募集资金的具体情况。 1 / 2 表决结果：赞成 9 票，反对 0 票，弃权 0 票。 一、董事会会议召开情况 采纳科技股份有限公司（以下简称"公司"）第三届董事会第二次会议通知 于 2023 年 8 月 11 日以邮件、电话等方式向各位董事发出，会议于 2023 年 8 月 23 日以现场会议结合通讯形式，在江苏省江阴市祝塘镇环西路 23 号采纳医疗办 公楼一楼会议室召开。本次会议由公司董事长陆军先生主持，会议应出席董事 9 人，实际出席董事 9 人（其中以通讯表决方式出席会议的董事人数 4 人，分别 为：侯鹏先生、刘斌先生、王尚虎先生、夏立扬先生），公司监事及部分高级管 理人员列席了会议。本次会议的召集、召开及表决符合《中 ...

| | | 占用方与上 | 上市公司核算的 | 2023 年期初占 | 2023 年半年度占 | 2023 年半年度 | 2023 年半年度 | 2023 年 | 6 月末 | 占用形成 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 非经营性资金占用 | 资金占用方名称 | 市公司的关 | | | 用累计发生金额 | 占用资金的利 | 偿还累计发生 | | | | 占用性质 | | | | 联关系 | 会计科目 | 用资金余额 | （不含利息） | 息（如有） | 金额 | 占用资金余额 | | 原因 | | | 控股股东、实际控制人及 | - | - | - | - | - | - | - | - | | - | 非经营性 | | 其附属企业 | - | - | - | - | - | - | - | - | | - | 非经营性 | | 小计 | - | - | - | - | - | - | - | - | | - | - | | 前控股股东、实际控制人 | - | - | - | - | ...

证券代码：301122 证券简称：采纳股份 公告编号：2023-071 采纳科技股份有限公司 2023 年半年度募集资金存放与使用情况的专项报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 单位：人民币万元 | | 项目 | | 序号 | 金额 | | --- | --- | --- | --- | --- | | 募集资金净额 | | A | | 109,726.24 | | 置换前期投入项目金额 | | B | 386.63 | | --- | --- | --- | --- | | 本期发生额 | 项目投入 | C1 | 8,803.33 | | | 永久补充流动资金划出金额 | C2 | 20,000.00 | | | 利息收入净额 | C3 | 943.76 | | 以前年度发生额 | 项目投入 | D1 | 12,134.07 | | | 永久补充流动资金划出金额 | D2 | 25,000.00 | | | 利息收入净额 | D3 | 1,400.58 | | 截至期末发生额 | 项目投入 | E1=B+C1+D1 | 21,324.03 | ...

Group 1: Project Progress and Capacity - The second phase project is located on Chenglu Road in Huashi Town, covering a planned area of 90,000 square meters, with the main structure completed and currently in the decoration phase. Some equipment has begun to arrive for installation and debugging. It is expected that part of the capacity will be released in the second half of 2023 [1] - After the capacity release of the second phase project, the company's product orders are expected to match. The product range includes three main sectors: medical devices, animal devices, and laboratory consumables [1] Group 2: Product Development and Market Position - The company has obtained a total of 27 FDA510K product registrations, ranking among the top in the domestic injection and puncture industry. Recently, the company passed FDA review and gained market access for a pen needle product, which can be used generally, not limited to insulin injection [3] - The company’s products cover a wide variety of categories and are continuously developed to meet customer needs. The customer base consists of globally recognized medical enterprises, establishing stable long-term cooperation [3] Group 3: Automation and Production Efficiency - The company is one of the early adopters of automated robotic storage systems and intelligent sterilization production lines in the country. The automation level of production is expected to further improve with the launch of the second phase project [3] Group 4: Financial Performance and Risks - The company's performance in the first quarter of this year declined year-on-year, primarily due to a temporary decrease in market demand and the impact of the Spring Festival holiday [4] - Exchange rate fluctuations primarily affect the company's export product pricing competitiveness and foreign exchange gains and losses. The company plans to enhance R&D investment and utilize financial tools to mitigate foreign exchange risk [4]

Financial Performance - The company's revenue for Q1 2023 was ¥66,839,280.56, representing a decrease of 52.79% compared to ¥141,589,832.60 in the same period last year[5] - Net profit attributable to shareholders was ¥15,878,407.77, down 59.62% from ¥39,324,380.01 year-on-year[5] - Total operating revenue for Q1 2023 was CNY 66,839,280.56, a decrease of 52.8% compared to CNY 141,589,832.60 in the same period last year[19] - Net profit for Q1 2023 was CNY 15,878,407.77, a decline of 59.6% compared to CNY 39,324,380.01 in Q1 2022[20] - The total comprehensive income for the first quarter was CNY 15,878,407.77, a decrease from CNY 39,324,380.01 in the previous period[21] - Basic and diluted earnings per share for the quarter were both CNY 0.17, down from CNY 0.46 in the previous period[21] Cash Flow and Assets - The net cash flow from operating activities increased significantly to ¥38,212,822.55, a 5,374.04% improvement from -¥724,544.89 in the previous year[5] - The total cash and cash equivalents at the end of Q1 2023 amounted to CNY 282,245,196.54, down from CNY 355,590,390.56 at the beginning of the year, representing a decrease of approximately 20.5%[15] - The ending balance of cash and cash equivalents was CNY 282,245,196.54, down from CNY 802,495,998.92 in the previous period[23] - Cash inflow from investment activities totaled CNY 377,945,720.28, compared to CNY 100,200,000.00 in the previous period[23] - Cash outflow from investment activities was CNY 487,061,256.80, down from CNY 527,604,403.50 in the previous period[23] - The net cash flow from investment activities was negative CNY 109,115,536.52, an improvement from negative CNY 427,404,403.50 in the previous period[23] Assets and Liabilities - The company's total assets at the end of the reporting period were ¥1,847,147,895.30, a slight increase of 0.20% from ¥1,843,375,847.83 at the end of the previous year[5] - Total liabilities decreased to CNY 94,926,248.64 from CNY 107,032,608.94, indicating a reduction in financial obligations[17] - The company's total equity increased to CNY 1,752,221,646.66 from CNY 1,736,343,238.89, showing a positive trend in shareholder value[17] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 6,109, with the top shareholder holding 28.29% of the shares[10] - The top shareholder, Jiangyin New Guolian Group Co., Ltd., holds 3,157,900 shares, representing 3.36% of the total shares[12] - The company has a total of 10 major shareholders, with the largest holding being 6,000,000 shares by Zhao Hong, accounting for 6.38%[12] Investment and Expenses - The company reported a significant increase in investment income, which rose by 2,056.02% to ¥6,568,470.28, attributed to returns from newly purchased financial products[9] - The company experienced a 601.03% increase in financial expenses, totaling ¥1,067,454.17, mainly due to increased foreign exchange losses[9] - Research and development expenses were CNY 4,784,955.79, slightly down from CNY 4,889,125.57 in the previous year[20] Future Outlook and Strategy - The company has not provided specific future outlook or performance guidance for the upcoming quarters[14] - The company plans to focus on market expansion and new product development as part of its future strategy[20] Other Information - The company has not disclosed any new product developments or technological advancements during this quarter[14] - There are no updates on market expansion or mergers and acquisitions in the current report[14] - The first quarter report was not audited[24]

Financial Performance - The company's operating revenue for 2022 was ¥465,485,537.41, representing a 5.30% increase compared to ¥442,051,932.24 in 2021[21]. - Net profit attributable to shareholders for 2022 was ¥161,868,649.81, a 23.86% increase from ¥130,681,695.99 in 2021[21]. - The net profit after deducting non-recurring gains and losses was ¥139,054,676.08, up 10.92% from ¥125,366,249.94 in 2021[21]. - The total assets at the end of 2022 reached ¥1,843,375,847.83, a significant increase of 200.90% from ¥612,622,396.12 at the end of 2021[21]. - The net assets attributable to shareholders increased by 240.38% to ¥1,736,343,238.89 from ¥510,124,479.38 in 2021[21]. - The company reported a basic earnings per share of ¥1.76, down 4.86% from ¥1.85 in 2021[21]. - The weighted average return on equity decreased to 10.28% from 29.38% in 2021, a decline of 19.10%[21]. - The company experienced a net cash flow from operating activities of ¥138,881,985.74, which is a decrease of 13.23% compared to ¥160,053,823.98 in 2021[21]. Market Position and Industry Insights - The company is positioned in the specialized equipment manufacturing industry, focusing on medical devices, animal instruments, and laboratory consumables[30]. - The global market for injection and puncture products is projected to grow from $14.58 billion in 2019 to $25.7 billion by 2026, with a compound annual growth rate of 8.5%[32]. - The global veterinary vaccine sales reached approximately $6.935 billion in 2018, with a year-on-year growth of 5.11%[35]. - The global veterinary injection and puncture device market grew from $2.65 billion in 2014 to $3.37 billion in 2019, with a compound annual growth rate (CAGR) of 5.0%[35]. - The Chinese veterinary injection and puncture device market increased from ¥1.76 billion in 2014 to ¥2.47 billion in 2019, with a CAGR of 7.0%[36]. - The market size of China's veterinary injection device market is expected to reach ¥3.51 billion by 2024[36]. - The global laboratory consumables market grew from $28.341 billion in 2016 to $51.233 billion in 2021, with an expected annual growth rate of 15%[39]. - The company holds a leading position in the domestic veterinary injection device market, ranking first with a significant market share in 2019[42]. Research and Development - The company has established a research and development system focused on market needs, with dedicated centers for veterinary puncture devices and safety self-destruct syringes[62]. - The company is developing a safety indwelling needle aimed at reducing patient discomfort and preventing the spread of bloodborne diseases, with product molds already completed and CE registration in progress[87]. - A safety structure syringe is under development, designed to prevent accidental injuries and improve product competitiveness, with design and sample production phases ongoing[87]. - The company has obtained 26 FDA 510K registrations for its products, leading the industry in this regard[90]. - The company's R&D investment reached CNY 19,733,928.29 in 2022, accounting for 4.24% of its operating revenue[89]. - The number of R&D personnel increased to 118 in 2022, representing a growth of 18.07% compared to 2021[89]. Production and Quality Control - The company maintains a strict quality control process throughout production, adhering to ISO13485 and FDA standards[52]. - The company has established a comprehensive quality management system, certified by ISO13485 and MDSAP[64]. - The company has a production facility exceeding 68,000 square meters, with over 40,000 square meters meeting GMP standards[67]. - The company emphasizes a production model based on customer orders, adopting a "sales-driven production" approach to ensure product quality and efficiency[52]. Cash Flow and Investment Activities - The total cash inflow from operating activities in 2022 was approximately ¥512.06 million, an increase of 8.19% compared to ¥473.28 million in 2021[98]. - The total cash outflow from operating activities in 2022 was approximately ¥373.18 million, representing a 19.14% increase from ¥313.23 million in 2021[98]. - The cash inflow from investment activities surged to approximately ¥1.35 billion in 2022, a dramatic increase of 14,052.37% compared to ¥9.52 million in 2021[98]. - The cash outflow from investment activities in 2022 was approximately ¥2.34 billion, a significant rise of 1,545.29% from ¥142.15 million in 2021[98]. - The net cash flow from investment activities was approximately -¥991.91 million in 2022, worsening from -¥132.64 million in 2021, indicating a 647.84% increase in negative cash flow[98]. Governance and Compliance - The company emphasizes information disclosure, adhering to legal requirements to provide accurate and timely information to all shareholders[144]. - The company maintains an independent governance structure, ensuring operational independence from its controlling shareholder and actual controller[143]. - The board of directors consists of 9 members, including 3 independent directors, ensuring compliance with legal and regulatory requirements[140]. - The supervisory board is composed of 3 members, including 1 employee representative, fulfilling its responsibilities to protect shareholder interests[142]. Employee Management and Compensation - The total number of employees at the end of the reporting period was 689, with 352 in the parent company and 337 in major subsidiaries[182]. - The company has a competitive salary policy, combining base salary and performance-based pay, with salaries determined by job importance and company performance[184]. - The company plans to attract high-level technical, management, and marketing talents through competitive compensation and training programs over the next three years[185]. - The total pre-tax remuneration for directors, supervisors, and senior management amounted to CNY 3.0655 million[172]. Future Strategies and Goals - The company plans to increase R&D investment to enhance product competitiveness and profitability, aiming to mitigate risks from potential trade tensions and tariffs[128]. - The company aims to expand its product offerings and enhance competitiveness through innovative R&D initiatives[88]. - The company is focused on expanding its market presence in Southeast Asia, targeting a 10% market share by the end of 2023[175]. - The company plans to enhance its online sales platform, aiming for a 40% increase in e-commerce revenue in 2023[175].